Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter Sells 27,000 Shares

Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) CEO James Richard Porter sold 27,000 shares of the company's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $75.99, for a total transaction of $2,051,730.00. Following the completion of the transaction, the chief executive officer now owns 249,062 shares in the company, valued at approximately $18,926,221.38. This trade represents a 9.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

James Richard Porter also recently made the following trade(s):

• On Monday, January 6th, James Richard Porter sold 17,301 shares of Nuvalent stock. The stock was sold at an average price of $79.68, for a total value of $1,378,543.68.
• On Monday, December 16th, James Richard Porter sold 27,000 shares of Nuvalent stock. The stock was sold at an average price of $86.61, for a total transaction of $2,338,470.00.

Nuvalent Price Performance

NUVL traded down $0.15 during trading hours on Friday, reaching $75.84. 504,511 shares of the stock traded hands, compared to its average volume of 561,346. Nuvalent, Inc. has a fifty-two week low of $61.79 and a fifty-two week high of $113.51. The company has a market cap of $5.39 billion, a price-to-earnings ratio of -21.86 and a beta of 1.38. The firm's fifty day simple moving average is $86.74 and its two-hundred day simple moving average is $87.15.

Nuvalent (NASDAQ:NUVL - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.35). During the same quarter in the prior year, the business posted ($0.59) earnings per share. On average, research analysts predict that Nuvalent, Inc. will post -3.86 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. HC Wainwright restated a "buy" rating and set a $110.00 price objective on shares of Nuvalent in a report on Friday. UBS Group initiated coverage on Nuvalent in a research note on Thursday, October 24th. They set a "neutral" rating and a $100.00 price target for the company. BMO Capital Markets lifted their price objective on Nuvalent from $132.00 to $134.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. raised their price target on shares of Nuvalent from $100.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, October 4th. Finally, Wedbush reissued an "outperform" rating and issued a $115.00 price objective on shares of Nuvalent in a research report on Monday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Nuvalent has a consensus rating of "Moderate Buy" and a consensus target price of $112.36.

Hedge Funds Weigh In On Nuvalent

A number of institutional investors have recently made changes to their positions in NUVL. Edgestream Partners L.P. bought a new stake in shares of Nuvalent in the second quarter worth $1,191,000. Y Intercept Hong Kong Ltd acquired a new position in Nuvalent during the 3rd quarter worth $1,255,000. Lord Abbett & CO. LLC increased its position in shares of Nuvalent by 29.5% in the 3rd quarter. Lord Abbett & CO. LLC now owns 308,362 shares of the company's stock worth $31,546,000 after purchasing an additional 70,157 shares during the last quarter. Citigroup Inc. raised its stake in shares of Nuvalent by 14.9% in the 3rd quarter. Citigroup Inc. now owns 94,534 shares of the company's stock valued at $9,671,000 after purchasing an additional 12,256 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Nuvalent by 149.0% during the third quarter. Barclays PLC now owns 68,107 shares of the company's stock worth $6,968,000 after purchasing an additional 40,754 shares during the last quarter. 97.26% of the stock is owned by institutional investors and hedge funds.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.